SOP for Bacteriology, Mycology & AST: excerpts from WHO toolkit, 2026

Disclaimer: This post is for academic purposes only. Please read the original document if you intend to use them for clinical purposes.

This document summarises the 2026 WHO Toolkit of Standard Operating Procedures (SOPs) for Bacteriology, Mycology and Antimicrobial Susceptibility Testing (AST) to strengthen global laboratory systems and diagnostic capacity. Developed under the umbrella of the WHO’s Antimicrobial Resistance (AMR) Diagnostic Initiative, this comprehensive package offers clinical laboratories globally applicable, quality-assured guidelines to address bacterial and fungal infections alongside emerging AMR threats. It comprises over 70 SOPs accompanied by visual bench reference guides and decision-tree flow charts. Built on widely accessible conventional diagnostic methods while integrating options for automated systems and Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), the package aligns with standards set by the Clinical and Laboratory Standards Institute (CLSI), the European Committee on Antimicrobial Susceptibility Testing (EUCAST), and ISO-15189. It spans the complete diagnostic continuum: pre-analytical specimen collection/transport, processing of 14 distinct specimen types, phenotypic identification, susceptibility testing, priority resistance mechanism detection, quality control, biosafety, and critical results reporting. Prior to routine implementation, every SOP must undergo local review, pretesting, and verification or validation within the laboratory’s specific operational framework.

Advertisement:

I. Background:

In May 2023, the 76th World Health Assembly adopted resolution urging Member States to strengthen diagnostic capacity and address critical barriers to quality and diagnostic access. In response, the WHO Department of Antimicrobial Resistance launched the AMR Diagnostic Initiative to bolster global diagnostic capacity, laboratory infrastructure, and equitable service delivery.

Objectives:

  • Elevate Diagnostics: Position clinical diagnostics at the forefront of global responses to AMR, directly supporting patient care, antimicrobial stewardship, infection prevention and control (IPC), and routine surveillance.
  • Equitable Access: Ensure universal access to safe, affordable, quality-assured testing for common bacterial and fungal pathogens across all health system tiers.
  • Standardization: Mitigate diagnostic errors and inter-laboratory variability resulting from resource constraints, improper specimen handling, transport delays, and unstandardized practices.

II. Scope, Technical Alignment, and Target Audience:

Scope:

The toolkit provides standardized, actionable operational guidelines covering twelve key operational domains:

  1. Specimen collection, transport, and pre-analytical management
  2. Specimen processing, culture, and interpretation
  3. Microscopy and conventional phenotypic identification testing
  4. Organism-specific bacterial identification and typing
  5. Fungal identification and specialized fungal diagnostics
  6. Antimicrobial and antifungal susceptibility testing (AST/AFST)
  7. Detection and confirmation of priority resistance mechanisms
  8. Isolate preservation and control-organism management
  9. Equipment maintenance, sterilization, and process quality control
  10. Biosafety, chemical decontamination, and laboratory hygiene
  11. Results review, communication, authorization, and reporting
  12. Visual bench reference guides paired with core laboratory procedures

Technical Alignment:

The toolkit’s procedures conform to recognized international standards and guidelines:

  • CLSI & EUCAST: Standardized performance thresholds for antibacterial disc/gradient diffusion and yeast susceptibility testing.
  • ISO-15189: Technical requirements for quality management, competence, and reliability in medical laboratories.
  • WHO Laboratory Biosafety Manual (4th Edition): Principles of risk assessment, personal protective equipment (PPE), containment, and biosafety cabinet (BSC) utilization.

Target Audience:

The primary audience includes clinical microbiology laboratories, microbiologists, laboratory managers, scientists, technologists, quality assurance officers, and AMR surveillance networks. Secondary audiences include specimen collectors, clinical staff, IPC teams, antimicrobial stewardship committees, and public health policy bodies.

III. Development and Public Consultation:

The toolkit was compiled through an evidence-informed process coordinated by WHO Headquarters (Department of Antimicrobial Resistance)

Development:

  • Baseline SOPs: The Diagnostic Microbiology Development Program (DMDP, USA) provided initial SOP drafts and bench aids.
  • Collaborating Centre Support: Supplementary SOPs were provided by the WHO Collaborating Centre for AMR (South Africa) and reviewed with support from the WHO Collaborating Centre for Reference & Research on AMR and Healthcare Associated Infections (UK).
  • Expert Review Panel: Each SOP underwent independent review by three subject-matter experts. Complex technical discrepancies were submitted to a five-member consensus panel. Participating experts represented diverse geographic regions and LMIC contexts across 20+ countries.
  • Funding: Financial support was provided by the Government of Germany and the Novo Nordisk Foundation.

Public Consultation (June–July 2026):

An online public consultation gathered structured feedback from 72 expert respondents across 27 countries in all six WHO regions:

  • Regional Distribution: Eastern Mediterranean (43.1%), African (18.1%), South-East Asia (12.5%), European (11.1%), Western Pacific (8.3%), Region of the Americas (6.9%).
  • Sector Representation: 87.5% of respondents worked within the public sector (or combined public/private roles), including clinical pathologists, laboratory managers, and public health officials.
  • Feedback Metrics: 31 respondents submitted 402 detailed technical comments, leading to refined navigation, updated citations, and clarified setting applicability.
  • Implementation Intent: 91% of respondents reported being likely or very likely to implement/adapt the toolkit SOPs, and 96% indicated they would recommend the toolkit to professional peers.

IV. Implementation Framework and Governance

Laboratories must systematically evaluate, adapt, and formally approve each SOP before adopting it into routine clinical workflows.

                        [ Start: Laboratory Decision Process ]
                                          |
                    Does the laboratory have an approved SOP for this test?
                                    /           \
                                  NO             YES
                                 /                 \
  Review toolkit SOP against national      Compare current SOP with toolkit SOP,
  regs, accreditation, & resources          manufacturer rules, & standards
                 |                                   |
    Can toolkit SOP be used as written?    Are there gaps in technical/quality rules?
          /                \                     /               \
        YES                 NO                 YES                NO
        /                    \                  |                  \
  Adopt toolkit         Adapt toolkit       Revise current SOP    Continue using current
  SOP as written        SOP for local gaps  or replace with       approved controlled
        \                    /              toolkit SOP           SOP
         \                  /                   |                  |
    [ Pretest SOP; Verify or Validate ] <-------+                  |
                 |                                                 |
    [ Approve & Issue under Document Control ]                     |
                 |                                                 |
    [ Train Staff & Assess Competency ]                            |
                 |                                                 |
                 +-------------------------------------------------+
                                 |
              [ Execute Approved & Controlled SOP ]
                                 |
                      ( Periodic Review Loop )

Checklists for Rollout:

Checklist 1: Laboratory-Level Implementation Requirements

  • Document Control: Assign a unique identifier, version number, effective date, and authorization signature to every approved SOP.
  • Staff Training & Competence: Conduct structured practical training and verify competence prior to releasing an SOP for clinical workflow; maintain training records within the Laboratory Quality Management System (LQMS).
  • Point-of-Use Access: Distribute current approved SOPs and linked bench reference guides to active work stations; withdraw and archive superseded versions. Bench reference guides must supplement, not replace, full SOPs.
  • Method Verification/Validation: Pretest all SOPs. Perform verification for SOPs adopted as written; perform validation if procedural adaptations affect assay performance.
  • Quality Control & Biosafety Integration: Execute internal quality control (IQC), fulfill equipment maintenance requirements, and enforce safety box measures (e.g., compulsory Biosafety Cabinet usage).
  • Supportive Supervision: Monitor compliance using audits, measurable context-specific targets, and continuous feedback loops.

Checklist 2: National and Network-Level Governance

  • Governance Mechanism: Establish a national technical committee to coordinate review, adaptation, endorsement, and repository distribution across the laboratory network.
  • Harmonized Standards: Align SOP content with national AMR surveillance guidelines, national referral pathways, and tiered network capabilities.
  • Cross-Laboratory Monitoring: Oversee implementation progress across participating health centers using standardized quality metrics and audit frameworks.

V. The End-to-End Testing Pathway

The toolkit maps clinical microbiology workflows across pre-analytical, analytical, and post-analytical phases to minimize diagnostic error and ensure actionable results:

                  [ Specimen Collection or Isolate Referral ]
                                       |
                   [ Transport, Receipt & Acceptance Assessment ]
                                       |
                       Are acceptance requirements met?
                             /                  \
                           YES                   NO
                           /                      \
             [ Specimen/Isolate Processing ]   [ Hold specimen/isolate, document deviation, ]
                           |                   [ reject, request new sample, or process    ]
              +------------+------------+      [ under specified emergency conditions      ]
              |                         |
    [ Bacteriology Pathway ]   [ Mycology Pathway ]
              |                         |
     Bacterial Identification    Fungal Identification & Diagnostics
              |                         |
    Antimicrobial Susceptibility Antifungal Susceptibility Testing (if indicated)
    Testing (if indicated)              |
              |                         |
              +------------+------------+
                           |
            [ Quality Control & Validity Review ]
                           |
   [ Results Review, Urgent Notification (if required), & Authorization ]

Workflow Phases:

  1. Pre-Analytical: Specimen collection, safe transport, receipt assessment, and stringent rejection criteria application.
  2. Analytical: Specimen processing, primary culture inoculation, staining/microscopy, phenotypic or automated identification, and AST/AFST execution.
  3. Quality Control: In-line validation of media, reagents, and equipment using reference control organisms.
  4. Post-Analytical: Verification of results against clinical presentation, technical report review, immediate protocol-driven communication of critical results, and secure entry into Laboratory Information Systems (LIS).

VI. Quality Assurance, Biosafety, and Document Maintenance

Quality Management System (QMS):

  • Internal Quality Control (IQC): Active routine use of documented control strains to verify reagent reactivities, stain integrity, and culture media performance.
  • External Quality Assessment (EQA): Mandatory participation in external proficiency testing programs to benchmark precision and accuracy.
  • Equipment Management: Documented calibration, preventative maintenance, and autoclave efficacy monitoring using physical, chemical, and biological indicators.

Laboratory Biosafety:

  • Safety Boxes: Highlighted safety warnings must appear prominently on the front page of each SOP and be reinforced within specific execution steps.
  • Hazard Containment: High-risk manipulation of volatile reagents or aerosol-generating procedures involving pathogens (e.g., Burkholderia pseudomallei or Candida auris) strictly mandate Biosafety Level 2/3 precautions and certified Biosafety Cabinets (BSCs).
  • Chemical Hygiene: Exact dilution protocols for laboratory disinfectants (e.g., working bleach solutions) and decontaminating reusable protective wear (lab coats).

Post-Analytical Reporting and Urgent Communication

  • Critical Results (SOP G06): Protocols establishing immediate notification pathways for life-threatening findings (e.g., positive blood cultures, sterile body fluid pathogens, or detection of priority resistance mechanisms).
  • Report Review (SOP G07): Structured administrative and technical verification checks before releasing patient data.
  • Data Standards: Alignment of LIS configurations with national surveillance parameters and WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) metrics.

Review and Maintenance:

SOPs must be re-evaluated on a defined schedule (annually or biennially) within the LQMS. Immediate mandatory revisions are triggered by updates to CLSI/EUCAST guidelines, changes in equipment/reagent platforms, identified nonconformities, or post-incident root-cause analyses.

VII. SOPs:

The toolkit SOPs are assigned specific prefix codes designating their technical category:

  • B: Bacteriology
  • M: Mycology
  • G: General Laboratory
  • Q: Quality Management

1. Specimen Collection, Transport, and Pre-Analytical Management:

CodeTitleFunctional Description
G01Specimen collection, transport and processingMicrobiological specimen collection, transport, receipt, processing, and acceptance/rejection criteria.
G02Collection of blood for culturesStandard procedures for blood culture collection across adult, pediatric, infant, and neonatal populations.
G03Transport of infectious substancesSafety packaging, labeling, hazard compliance, and documentation for transporting infectious materials.

2. Specimen Processing, Culture, and Interpretation:

CodeTitleFunctional Description
B01Processing of blood cultures using conventional and automated methodsWork-up, incubation, and processing of blood cultures via conventional manual and automated blood-culture systems.
B02Processing of cerebrospinal fluidDirect examination of CSF for bacterial/fungal pathogens, including microscopy, cell counts, and differential analysis.
B03Processing of sterile body fluids other than cerebrospinal fluidInvestigation of sterile fluids (pleural, synovial, peritoneal, pericardial, and amniotic fluids).
B04Processing of wound swabs and pus aspiratesProcessing, culture, and interpretation of skin and soft-tissue infection specimens.
B05Processing of tissues and biopsiesProcessing techniques for tissue/biopsy specimens from skin and deep soft-tissue infections.
B06Processing of sputum specimensProcessing expectorated sputum to isolate common bacterial causes of lower respiratory tract infections.
B07Processing of lower respiratory tract specimens other than sputumCulture and diagnostic interpretation of BAL, tracheal aspirates, bronchial washings, and related non-sputum samples.
B08Processing of throat swabsProcessing throat swabs targeting Streptococcus pyogenes and selected upper respiratory pathogens.
B09Processing of eye specimensBacterial culture of ocular samples, with brief guidance for investigating Acanthamoeba and fungal eye infections.
B10Processing of ear specimensProcessing ear swabs and middle-ear aspirates for otic infection diagnostics.
B11Processing of urine specimensInoculation, colony counting, interpretation, and reporting for routine, catheterized, and special urine samples.
B12Processing of central line catheter tipsSemi-quantitative culture of central venous catheter tips to investigate intravascular catheter-related infections.
B13Processing of genital swabs and associated specimens, including detection of group B streptococci carriage during pregnancyCulturing genital specimens for STI and non-STI etiologies, including Group B Streptococcus screening in pregnant women.
B14Processing of stool specimensCulture, isolation, and preliminary identification of bacterial enteric pathogens from fecal specimens.

3. Microscopy and Conventional Phenotypic Identification Tests:

CodeTitleFunctional Description
B15Bacitracin testPresumptive differentiation of Group A beta-hemolytic streptococci from other beta-hemolytic streptococci.
B16Bile solubility testRapid bile-solubility testing for the presumptive identification of Streptococcus pneumoniae.
B17CAMP testPerformance of the CAMP assay for presumptive identification of Streptococcus agalactiae (Group B streptococci).
B18Coagulase testTube and slide coagulase testing to differentiate Staphylococcus aureus from coagulase-negative staphylococci (CoNS).
B19Citrate testSodium citrate utilization testing for biochemical identification within Enterobacterales.
B20Microscopy examinationDiagnostic procedures for Gram staining, wet mounts, KOH preparations, and direct cell counting.
B21Indole testSpot and tube indole tests for detecting bacterial tryptophanase activity.
B22Kligler iron agar testKIA differentiation of gram-negative bacilli based on glucose/lactose fermentation, gas, and H₂S production.
B23Potassium hydroxide string testRapid non-staining KOH string assay to differentiate gram-negative from gram-positive bacterial cell walls.
B24Lysine iron agar testLIA testing to determine lysine decarboxylation, lysine deamination, and H₂S production in enteric bacilli.
B25Motility testSemi-solid media and hanging-drop methods for evaluating bacterial motility.
B26Optochin testOptochin susceptibility testing to differentiate Streptococcus pneumoniae from alpha-hemolytic viridans streptococci.
B27Oxidase testCytochrome c oxidase testing for differentiating pseudomonads and other non-fermenting bacilli.
B28Pyrrolidonyl arylamidase (PYR) testRapid PYR assay for identifying Group A streptococci, enterococci, and select gram-positive cocci.
B29Urease testDetection of bacterial urease enzymes utilizing Christensen’s urea medium.
B30Aesculin hydrolysis testBile aesculin testing for identifying enterococci and Group D streptococci.
B31Catalase testHydrogen peroxide breakdown testing to differentiate staphylococci (catalase-positive) from streptococci (catalase-negative).
B32Deoxyribonuclease testDNase agar testing to support the identification of Staphylococcus aureus and Serratia species.
B33O-nitrophenyl-β-D-galactopyranoside (ONPG) testONPG test for detecting beta-galactosidase in late or slow lactose-fermenting organisms.
B34X and V factors testFactor X (hemin) and V (NAD) requirement testing for identifying and differentiating Haemophilus species.
B35Analytical Profile Index (API)Commercial micro-biochemical test strips (e.g., API 20E) for standardized bacterial identification.

4. Identification of Common Bacterial Pathogens:

CodeTitleFunctional Description
B36Identification of EnterobacteralesSystematic phenotypic identification algorithms for medically important Enterobacterales.
B37Identification of non-fermenting gram-negative bacilliIdentification pathways for Pseudomonas, Acinetobacter, and related non-fermenting bacilli.
B38Identification of Neisseria speciesDiagnostic work-up for isolating and confirming Neisseria gonorrhoeae and Neisseria meningitidis.
B39Identification of gram-positive cocciIntegrated phenotypic identification of staphylococci, streptococci, and enterococci.
B40Salmonella serotypingSerological identification of Salmonella isolates via somatic (O) and flagellar (H) antigen characterization.
B41Identification of Burkholderia pseudomalleiCulture, biochemical, and safety protocols for isolating and confirming Burkholderia pseudomallei.
B48Identification of Haemophilus speciesDifferential identification of Haemophilus species and direct specimen detection of Haemophilus influenzae type b.

5. Antimicrobial and Antifungal Susceptibility Testing (AST / AFST):

CodeTitleFunctional Description
B42Disc diffusion antimicrobial susceptibility testingKirby-Bauer disc diffusion methodology, zone measurement, and CLSI/EUCAST interpretation rules.
B43D-zone test for the detection of inducible clindamycin resistanceDisc-approximation test (erythromycin-clindamycin) for inducible macrolide-lincosamide-streptogramin B (iMLSB) resistance.
B49Gradient diffusion strip antimicrobial susceptibility testingMinimum Inhibitory Concentration (MIC) determination using antimicrobial gradient strips.
M07Antifungal susceptibility testing of Candida species using commercial broth microdilution (Sensititre)Broth microdilution testing for Candida species using commercial Sensititre panels.
M08Antifungal susceptibility testing of Candida species using gradient diffusion methodQuantitative MIC determination for Candida isolates using antifungal gradient diffusion strips.
M09Antifungal susceptibility testing of yeasts by disc diffusion methodStandardized disc diffusion methodology for antifungal susceptibility testing of clinical yeast isolates.

6. Detection and Confirmation of Priority Resistance Mechanisms:

CodeTitleFunctional Description
B44Detection and confirmation of extended-spectrum beta-lactamase (ESBL)-producing EnterobacteralesPhenotypic screening and disc-combination confirmatory testing for ESBL production.
B45Detection and confirmation of carbapenemase-producing organismsScreening and phenotypic confirmation tests (e.g., mCIM, inhibitor-based methods) for carbapenemase production.
B46Detection and confirmation of colistin resistance in gram-negative bacteriaStandardized phenotypic testing (e.g., broth microdilution/selective broth methods) for colistin resistance.
B47Detection and confirmation of AmpC beta-lactamase production in EnterobacteralesPhenotypic screening and confirmatory differentiation of plasmid-mediated and inducible AmpC beta-lactamases.

7. Biosafety, Decontamination, and Laboratory Hygiene:

CodeTitleFunctional Description
G04Bleach dilutionStep-by-step procedures for preparing sodium hypochlorite working solutions for routine surface disinfection.
G05Decontamination of laboratory coatsProtocols for decontaminating, laundering, and handling contaminated laboratory coats and gowns.

8. Results Review, Communication, and Reporting:

CodeTitleFunctional Description
G06Reporting critical resultsImmediate notification, logging, and audit verification procedures for urgent/critical laboratory findings.
G07Report reviewTechnical and administrative quality check criteria governing report authorization prior to clinical release.

9. Yeast Identification and Fungal Diagnostics:

CodeTitleFunctional Description
M01Identification and antifungal susceptibility testing of yeasts using the VITEK 2 automated systemAutomated identification and AFST of clinical yeast isolates utilizing VITEK 2 cards.
M02Identification of yeasts using the VITEK MS prime automated system (plus antifungal susceptibility testing using FlexPrep)MALDI-TOF MS identification of yeasts via VITEK MS prime and integration with FlexPrep AFST.
M03Identification of yeasts using AuxacolorColorimetric sugar-assimilation biochemical panel testing for yeast identification.
M04Identification of yeasts using the Bruker Biotyper matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) instrumentMass spectrometry identification workflows for yeasts using the Bruker Biotyper platform.
M05Identification of yeasts using API 20C AUXCommercial carbohydrate assimilation test strips for identifying clinically relevant yeasts.
M06Molecular identification of yeast cultureNucleic acid extraction and target sequencing/PCR for definitive species identification of yeast cultures.
M10Presumptive identification of Candida species using chromogenic agarDifferential isolation and presumptive identification of Candida species, including Candida auris, on chromogenic media.
M11Germ tube test for presumptive identification of Candida speciesRapid germ-tube production assay for differentiating Candida albicans and Candida dubliniensis from other yeasts.
M13Cryptococcal antigen lateral flow assayRapid qualitative and semi-quantitative detection of cryptococcal capsular antigen in CSF and serum via LFA.

10. Isolate Preservation and Control-Organism Management:

CodeTitleFunctional Description
M12Storage of yeast isolatesShort- and long-term preservation techniques (freezing, lyophilization, slants) for Candida and other yeast isolates.
Q01Bacterial isolate storage and maintenanceCryopreservation, slant maintenance, and recovery protocols for long-term biobanking of bacterial isolates.
Q02Management of quality-control organismsSourcing, subculturing, characterization, and storage of reference strains (ATCC/NCTC) for routine internal QC.

11. Equipment, Sterilization, and Process Quality Control:

CodeTitleFunctional Description
Q03Equipment quality controlCalibration, routine performance verification, temperature monitoring, and preventative maintenance for instruments.
Q04Performance quality and monitoring of autoclavePhysical, chemical, and biological indicator monitoring to verify autoclave sterilization and waste decontamination.

Citation: Toolkit of standard operating procedures for bacteriology, mycology and antimicrobial susceptibility testing. Geneva: World Health Organization; 2026. Licence: CC BY-NC-SA 3.0 IGO.

https://www.who.int/publications/i/item/9789240126343

Leave a Reply

Your email address will not be published. Required fields are marked *